Chemical analysis of a benzofuran derivative, 2-(2-ethylaminopropyl) benzofuran (2-EAPB), eight synthetic cannabinoids, five cathinone derivatives, and five other designer drugs newly detected in illegal products

Forensic Toxicology

Volumn 32, Issue 2, 2014, Pages 266-281

  Uchiyama, Nahoko ^a   Shimokawa, Yoshihiko ^a   Kawamura, Maiko ^a   Kikura Hanajiri, Ruri ^a   Hakamatsuka, Takashi ^a  

^a NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

Author keywords

2 (2 Ethylaminopropyl)benzofuran (2 EAPB); Cathinone derivative; Diclofensine; Diphenidine; Nitracaine; Synthetic cannabinoid

Indexed keywords

1 BENZYLPIPERIDINE; 2 (2 ETHYLAMINOPROPYL)BENZOFURAN; 4 FLUORO ALPHA PHPP; 4 METHOXY ALPHA PHPP; 4 METHOXY ALPHA POP; 5 CHLORO AB PINACA; 5 FLUORO AB PINACA; 5 FLUORO AMB; 5 FLUORO NNEI INDAZOLE DERIVATIVE; AB CHMINACA; ACETYLFENTANYL; ALPHA PHP; AM 2201 INDAZOLE DERIVATIVE; BENZOFURAN DERIVATIVE; CANNABINOID DERIVATIVE; CATHINONE; DESIGNER DRUG; DICLOFENSINE; DIPHENIDINE; DL 4662; FUB PB 22; ILLICIT DRUG; NITRACAINE; UNCLASSIFIED DRUG;

ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CHEMICAL ANALYSIS; CHEMICAL STRUCTURE; CONTROLLED STUDY; ELECTROSPRAY MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY; MASS FRAGMENTOGRAPHY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; TIME OF FLIGHT MASS SPECTROMETRY;

EID: 84906355910     PISSN: 18608965     EISSN: 18608973     Source Type: Journal    
DOI: 10.1007/s11419-014-0238-5     Document Type: Article

References (20)

1. Uchiyama N, Kikura-Hanajiri R, Kawahara N, Goda Y (2009) Identification of a cannabimimetic indole as a designer drug in a herbal product. Forensic Toxicol 27:61-66
2. Uchiyama N, Kawamura M, Kikura-Hanajiri R, Goda Y (2012) Identification of two new-type synthetic cannabinoids, N-(1-ad-amantyl)-1-pentyl-1H-indole-3- carboxamide (APICA) and N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide (APINACA), and detection of five synthetic cannabinoids, AM-1220, AM-2233, AM-1241, CB-13 (CRA-13), and AM-1248, as designer drugs in illegal products. Forensic Toxicol 30:114-125
3. Kikura-Hanajiri R, Uchiyama N, Kawamura M, Goda Y (2013) Changes in the prevalence of synthetic cannabinoids and cathinone derivatives in Japan until early 2012. Forensic Toxicol 31:44-53
4. Uchiyama N, Matsuda S, Wakana D, Kikura-Hanajiri R, Goda Y (2013) New cannabimimetic indazole derivatives, N-(1-amino-3-methyl-1-oxobutan-2-yl)-1- pentyl-1H-indazole-3-carboxamide (AB-PINACA) and N-(1-amino-3-methyl-1-oxobutan- 2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA), identified as designer drugs. Forensic Toxicol 31:93-100
5. Takahashi K, Uchiyama N, Fukiwake T, Hasegawa T, Saijou M, Motoki Y, Kikura-Hanajiri R, Goda Y (2013) Identification and quantitation of JWH-213, a cannabimimetic indole, as a designer drug in a herbal product. Forensic Toxicol 31:145-150
6. Uchiyama N, Matsuda S, Kawamura M, Kikura-Hanajiri R, Goda Y (2013) Two new-type cannabimimetic quinolinyl carboxylates, QUPIC and QUCHIC, two new cannabimimetic carboxamide derivatives, ADB-FUBINACA and ADBICA, and five synthetic cannabinoids detected with a thiophene derivative α-PVT and an opioid receptor agonist AH-7921 identified in illegal products. Forensic Toxicol 31:223-240
7. UNODC (2014) 2014 Global synthetic drugs assessment. Amphetamine-type stimulants and new psychoactive substances, May 2014. http://www.unodc.org/ documents/scientific/2014-Global-Synthetic-Drugs-Assessment-web.pdf. Accessed May 2014
8. EMCDDA (2014) European drug report 2014: trends and developments, May 2014. http://www.emcdda.europa.eu/attachements.cfm/att-228272-EN-TDAT14001ENN. pdf. Accessed May 2014
9. Uchiyama N, Matsuda S, Kawamura M, Kikura-Hanajiri R, Goda Y (2014) Identification of two new-type designer drugs, a piperazine derivative MT-45 (I-C6) and a synthetic peptide Noopept (GVS-111), with a synthetic cannabinoid A-834735, a cathinone derivative 4-methoxy-α-PVP and a phenethylamine derivative 4-methylbuphedrine from illegal products. Forensic Toxicol 32:9-18
10. Uchiyama N, Shimokawa Y, Matsuda S, Kawamura M, Kikura-Hanajiri R, Goda Y (2014) Two new synthetic cannabinoids, AM-2201 benzimidazole analog (FUBIMINA) and (4-methylpiperazin-1-yl)(1-pentyl-1H-indol-3-yl)methanone (MEPIRAPIM), and three phenethylamine derivatives, 25H-NBOMe 3,4,5-trimethoxybenzyl analog, 25B-NBOMe, and 2C-N-NBOMe, identified in illegal products. Forensic Toxicol 32:105-117
11. Uchiyama N, Matsuda S, Kawamura M, Shimokawa Y, Kikura-Hanajiri R, Aritake K, Urade Y, Goda Y (2014) Characterization of four new designer drugs, 5-chloro-NNEI, NNEI indazole analog, α-PHPP and α-POP, with 11 newly distributed designer drugs in illegal products. Forensic Sci Int 243:1-13
12. Uchiyama N, Kawamura M, Kikura-Hanajiri R, Goda Y (2013) URB-754: a new class of designer drug and 12 synthetic cannabinoids detected in illegal products. Forensic Sci Int 227:21-32
13. Frost JM, Dart MJ, Tietje KR, Garrison TR, Grayson GK, Daza AV, El-Kouhen OF, Yao BB, Hsieh GC, Pai M, Zhu CZ, Chandran P, Meyer MD (2010) Indol-3-ylcycloalkyl ketones: effects of N1 substituted indole side chain variations on CB2 cannabinoid receptor activity. J Med Chem 53:295-315
14. Buchler IP, Hayes MJ, Hegde SG, Hockerman SL, Jones DE, Kortum SW, Rico JG, Tenbrink RE, Wu KK (2009) Indazole derivatives as CB1 receptor modulators and their preparation and use in treatment of diseases. Patent: WO/2009/106980 September, 2009
15. Iversen L, Gibbons S, Treble R, Sedtola V, Huang X-P, Rolth BL (2013) Neurochemical profiles of some novel psychoactive substances. Eur J Pharmacol 700:147-151
16. Advisory Council on the Misuse of Drugs (ACMD) (2013) Benzofurans: a review of the evidence of use and harm. ACMD, London. https://www.gov.uk/ government/uploads/system/uploads/attachment-data/file/261783/ Benzofuran-compounds-report.pdf. Accessed May 2014
17. Power JD, Scott KR, Gardner EA, Curran McAteer BM, O'Brien JE, Brehon M, Talbot B, Kavanagh PV (2014) The syntheses, characterization and in vitro metabolism of nitracaine, methoxypiperamide and mephtetramine. Drug Test Anal. doi:10.1002/dta.1616
18. Nakachi N, Kiuchi Y, Inagaki M, Inazu M, Yamazaki Y, Oguchi K (1995) Effects of various dopamine uptake inhibitors on striatal extracellular dopamine levels and behaviors in rats. Eur J Pharmacol 281:195-203
19. Berger ML, Schweifer A, Rebernik P, Hammerschmidt F (2009) NMDA receptor affinities of 1,2-diphenylethylamine and 1-(1,2-diphenylethyl)piperidine enantiomers and of related compounds. Bioorg Med Chem 17:3456-3462
20. Kikura-Hanajiri R, Uchiyama N, Kawamura M, Goda Y (2014) Changes in the prevalence of new psychoactive substances before and after the introduction of the generic scheduling of synthetic cannabinoids in Japan. Drug Test Anal. doi:10.1002/dta.1584